Secreted expression of an active human interferon‐beta (HuIFNβ) in <i>Kluyveromyces lactis</i>

Madhavan, Aravind; Sukumaran, Rajeev

doi:10.1002/elsc.201500120

Cited by 11 publications

(2 citation statements)

References 27 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, cellobiohyrolase promoter from Trichoderma reesei has been used as hybrid promoter along with LAC4 promoter of K. lactis for the production of GFP [ 39 ]. Engineered LAC4 promoter with fungal signal peptide has been used for the production of human interferon β [ 40 – 42 ].…”

Section: Promoter Engineeringmentioning

confidence: 99%

Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up

et al. 2021

Self Cite

View full text Add to dashboard Cite

The manufacture of recombinant therapeutics is a fastest-developing section of therapeutic pharmaceuticals and presently plays a significant role in disease management. Yeasts are established eukaryotic host for heterologous protein production and offer distinctive benefits in synthesising pharmaceutical recombinants. Yeasts are proficient of vigorous growth on inexpensive media, easy for gene manipulations, and are capable of adding post translational changes of eukaryotes. Saccharomyces cerevisiae is model yeast that has been applied as a main host for the manufacture of pharmaceuticals and is the major tool box for genetic studies; nevertheless, numerous other yeasts comprising Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha, and Yarrowia lipolytica have attained huge attention as non-conventional partners intended for the industrial manufacture of heterologous proteins. Here we review the advances in yeast gene manipulation tools and techniques for heterologous pharmaceutical protein synthesis. Application of secretory pathway engineering, glycosylation engineering strategies and fermentation scale-up strategies in customizing yeast cells for the synthesis of therapeutic proteins has been meticulously described.

show abstract

Section: Promoter Engineeringmentioning

confidence: 99%

Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fructosyltransferase alpha-factor signal peptide Hypocaloric sweeteners [93] Arylsulfatase alpha-factor signal peptide Milk processing [94] Interferon-Beta Glucoamylase signal sequence Therapeutic applications [95] Table 4. Recent heterologous expression and secretion of recombinant proteins from mid2016-Feb2017.…”

Section: Kluyveromyces Lactismentioning

confidence: 99%

Secretion Mechanism across Wall

López-Vargas¹,

Kutralam-Muniasamy²,

Reyes³

et al. 2018

The Yeast Role in Medical Applications

View full text Add to dashboard Cite

Yeast organisms are widely explored by humans for different biotechnological applications. During their growth, they need to adapt and interact themselves with the environment medium. For this purpose, organisms uptake nutrients and at the same time secrete different molecules include proteins to extracellular medium. This phenomenon requires the use of specialized structures to regulate entry and exit of molecules called transporters. Two transporters, namely Proteins and Vesicles, are specialized in translocating molecules in and out across the wall. The knowledge of these systems is important and served to bring novel applications of yeast. Taking together, this book chapter is divided into two parts: at first, it primarily accounts on few examples of protein (carbohydrates and peroxisome proteins) and vesicle (intracellular and extracellular vesicles) transporters of yeasts. Second, it deals with the recent advances of yeast applications in diverse area of science.

show abstract

Strategies for humanizing glycosylation pathways and producing recombinant glycoproteins in microbial expression systems

Khan

Noordin

2018

Biotechnology Progress

View full text Add to dashboard Cite

Homogeneously glycosylated proteins are essential for analyzing the structure of N‐glycans, studying their consequences inside cells, and developing therapeutic glycoproteins. However, the isolation of glycoproteins with homogeneous glycans from human is difficult since glycoforms slightly differ from each other with respect to molecular weight and charge. Microbial expression systems have numerous benefits in expression technology and have gained great attention, because they are more adaptable to the biotechnology industry. While selecting an expression host, the glycosylation pattern must be taken into account, because glycosylation strongly depends on cellular production system and selected production clone. This review discussed the technological developments in glycoengineering of microbial expression systems for humanizing the glycosylation profile and highlighted the expression potential of Leishmania expression system. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 35: e2752, 2019.

show abstract

Secreted expression of an active human interferon‐beta (HuIFNβ) in Kluyveromyces lactis

Cited by 11 publications

References 27 publications

Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up

Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up

Secretion Mechanism across Wall

Strategies for humanizing glycosylation pathways and producing recombinant glycoproteins in microbial expression systems

Contact Info

Product

Resources

About